Search

Your search keyword '"Van Houtte, P."' showing total 1,350 results
Start Over Author "Van Houtte, P."
1,350 results on '"Van Houtte, P."'

203. A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.

Author

David Nauwelaers, Margriet Van Houtte, Bart Winters, Kim Steegen, Kurt Van Baelen, Ellen Chi, Mimi Zhou, Derek Steiner, Rachelle Bonesteel, Colin Aston, and Lieven J Stuyver

Subjects
Medicine, Science
Abstract

In order to determine phenotypic protease and reverse transcriptase inhibitor-associated resistance in HIV subtype C virus, we have synthetically constructed an HIV-1 subtype C (HIV-1-C) viral backbone for use in a recombinant virus assay. The in silico designed viral genome was divided into 4 fragments, which were chemically synthesized and joined together by conventional subcloning. Subsequently, gag-protease-reverse-transcriptase (GPRT) fragments from 8 HIV-1 subtype C-infected patient samples were RT-PCR-amplified and cloned into the HIV-1-C backbone (deleted for GPRT) using In-Fusion reagents. Recombinant viruses (1 to 5 per patient sample) were produced in MT4-eGFP cells where cyto-pathogenic effect (CPE), p24 and Viral Load (VL) were monitored. The resulting HIV-1-C recombinant virus stocks (RVS) were added to MT4-eGFP cells in the presence of serial dilutions of antiretroviral drugs (PI, NNRTI, NRTI) to determine the fold-change in IC50 compared to the IC50 of wild-type HIV-1 virus. Additionally, viral RNA was extracted from the HIV-1-C RVS and the amplified GPRT products were used to generate recombinant virus in a subtype B backbone. Phenotypic resistance profiles in a subtype B and subtype C backbone were compared. The following observations were made: i) functional, infectious HIV-1 subtype C viruses were generated, confirmed by VL and p24 measurements; ii) their rate of infection was slower than viruses generated in the subtype B backbone; iii) they did not produce clear CPE in MT4 cells; and iv) drug resistance profiles generated in both backbones were very similar, including re-sensitizing effects like M184V on AZT.

Published
2011
Full Text
View/download PDF

208. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

Author

A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, H. Clayson, P. de Vuyst, H. Dienemann, F. Galateau-Salle, C. Hennequin, G. Hillerdal, C. Le Pe´choux, L. Mutti, J-C. Pairon, R. Stahel, P. van Houtte, J. van Meerbeeck, D. Waller, and W. Weder

Subjects
Lung neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2010

209. SP-0205 B-QUATRO clinical audits: A Belgian success story?

Author

Vaandering, A., Batamuriza Almasi, A., Vermylen, A., Vanderstraeten, B., Weltens, C., Meunier, C., Verellen, D., Vandeputte, K., Van den Berghe, L., Van Dycke, M., Tomsej, M., Linthout, N., Deman, N., Van Houtte, P., Thysebaert, P., Cucchiaro, S., Derycke, S., Remouchamps, V., Bijdekerke, P., Scalliet, P., Vynckier, S., Lievens, Y., Vanhoutte, F., and Goemaere, E.

Published
2023
Full Text
View/download PDF

226. Lung Cancer

Author

Van Houtte, P., primary, Mornex, F., additional, Loubeyre, P., additional, Rocmans, P., additional, and Vaylet, F., additional

Published
2004
Full Text
View/download PDF

232. Positron Emission Tomography-Guided Radiosurgery: Early Experience with the Integration of Metabolic Data in the Dosimetry Planning with the Leksell Gamma Knife ®

Author

Levivier, M., primary, Wikler, D., additional, Goldman, S., additional, Massager, N., additional, Szeifert, G.T., additional, David, P., additional, Devriendt, D., additional, Desmedt, F., additional, Simon, S., additional, van Houtte, P., additional, and Brotchi, J., additional

Published
2002
Full Text
View/download PDF

234. CONTRIBUTORS

Author

AIFANTIS, ELIAS C., primary, ALTENBACH, HOLM, additional, ARCHAMBAULT, P., additional, ARRUDA, ELLEN M., additional, BATHIAS, C., additional, BAZANT, ZDENEK P., additional, BENALLAL, AHMED, additional, BERTRAM, ALBRECHT, additional, BERTHIER, YVES, additional, BESSON, B.J., additional, BESSELING, J.F., additional, BERVEILLER, M., additional, BILLARDON, RENÉ, additional, BODNER, SOL R., additional, BOYCE, MARY C., additional, BRECHET, YVES, additional, BROEK, DAVID, additional, BUI, HUY DUONG, additional, BURR, ALAIN, additional, BUSSO, ESTEBAN P., additional, CAILLETAUD, GEORGES, additional, CARVELLI, VALTER, additional, CESCOTTO, SERGE, additional, CHABOCHE, J.L., additional, CHAN, A.H.C., additional, CHOW, C.L., additional, CICONE, TRAIAN, additional, CRISTESCU, N.D., additional, COUSSY, OLIVIER, additional, COWIN, STEPHEN C., additional, CUNAT, CHRISTIAN, additional, DANGLA, PATRICK, additional, DARVE, FÉLIX, additional, DAFALIAS, YANNIS F., additional, DENIS, S., additional, DESAI, CHANDRA S., additional, DESMORAT, RODRIGUE, additional, DRAGON-LOUISET, MARTA, additional, DRUCKER, DANIEL C., additional, DVORAK, GEORGE J., additional, DUCHÉNE, L., additional, ELLYIN, FERNAND, additional, FISCHER, F.D., additional, FRANÇOIS, DOMINIQUE, additional, FRÊNE, JEAN, additional, GAUTIER, E., additional, GODINAS, A., additional, GROSS, DIETMAR, additional, HABRAKEN, ANNE MARIE, additional, HAUDIN, JEAN-MARC, additional, HAYHURST, D.R., additional, HILD, FRANÇOIS, additional, HIRSINGER, LAURENT, additional, HO, K., additional, HOLZAPFEL, GERHARD A., additional, IKEGAMI, KOZO, additional, INOUE, TATSUO, additional, ISHIKAWA, HIROMASA, additional, JENSEN, HENRIK MYHRE, additional, KATO, KOJI, additional, KLEPACZKO, JANUSZ R., additional, KNAUSS, W.G., additional, KRAJCINOVIC, DUSAN, additional, KREMPL, E., additional, KURTYKA, TADEUSZ, additional, LADEVÈZE, PIERRE, additional, LECKIE, FREDERICK A., additional, LEBLOND, J-B., additional, LEMAITRE, JEAN, additional, MAIER, GIULIO, additional, MARQUIS, DIDIER, additional, MANZARI, MAJID T., additional, MAZARS, JACKY, additional, MESLIN, FREDERIC, additional, MOLINARI, ALAIN, additional, MONASSE, BERNARD, additional, MUGHRABI, HAEL, additional, STALIN-MULLER, N., additional, MRÓZ, Z., additional, MURAKAMI, SUMIO, additional, NOVA, ROBERTO, additional, NEEDLEMAN, A., additional, NEMAT-NASSER, SIA, additional, OGDEN, R.W., additional, OHNO, NOBUTADA, additional, OLSCHEWSKI, J. URGEN, additional, OSSART, FLORENCE, additional, PASTOR, M., additional, PERZYNA, PIOTR, additional, PIJAUDIER-CABOT, GILLES, additional, PINEAU, A., additional, POITOU, ARNAUD, additional, RAHOUADJ, RACHID, additional, RAOUS, MICHEL, additional, ROUSSELIER, GILLES, additional, RUDNICKI, J.W., additional, SASAKI, KATSUHIKO, additional, SAVKOOR, A.R., additional, SCHAPERY, R.A., additional, SCHIRRER, ROBERT, additional, SCHLOGL, SABINE M., additional, SCHREFLER, B.A., additional, SIMONI, L., additional, SOFRONIS, PETROS, additional, SOCIE, DARRELL, additional, STOLZ, CLAUDE, additional, SUQUET, PIERRE M., additional, TALIERCIO, ALBERTO, additional, TANAKA, EIICHI, additional, TOKUDA, MASATAKA, additional, TVÉRGAARD, V., additional, VAN, K. DANG, additional, VAN DER GIESSEN, ERIK, additional, VAN HOUTTE, P., additional, VAN MIER, J.G.M., additional, VARDOULAKIS, IOANNIS, additional, VOYIADJIS, GEORGE Z., additional, WAUTERS, MICHAEL, additional, WEI, YONG, additional, WILLIS, J.R., additional, YOKOBORI, A. TOSHIMITSU, additional, YOKOBORI, TAKEO, additional, ZHANG, XING, additional, ZHAO, JUN, additional, ZHU, Y., additional, ZIENKIEWICZ, O.C., additional, and ŻYCZKOWSKI, MICHA, additional

Published
2001
Full Text
View/download PDF

240. First Use of Fragile Geologic Features to Set the Design Motions for a Major Existing Engineered Structure.

Author

Stirling, Mark W., Abbott, Elizabeth R., Rood, Dylan H., McVerry, Graeme H., Abrahamson, Norman A., Barrell, David J. A., Huso, Rand, Litchfield, Nicola J., Luna, Lisa, Rhoades, David A., Silvester, Peter, Van Dissen, Russ J., Van Houtte, Chris, and Zondervan, Albert

Abstract

We document the first use of fragile geologic features (FGFs) to set formal design earthquake motions for a major existing engineered structure. The safety evaluation earthquake (SEE) spectrum for the Clyde Dam, New Zealand (the mean 10,000 yr, ka, return period response spectrum) is developed in accordance with official guidelines and utilizes constraints provided by seven precariously balanced rocks (PBRs) located 2 km from the dam site and the local active Dunstan fault. The PBRs are located in the hanging wall of the fault. Deterministic PBR fragilities are estimated from field measurements of rock geometries and are the dynamic peak ground accelerations (PGAs) required for toppling. PBR fragility ages are modeled from 10Be cosmogenic isotope exposure dating techniques and are in the range of 24-66 ka. The fragility ages are consistent with the PBRs having survived at least two large Dunstan fault earthquakes. We develop a PGA-based fragility distribution from all of the PBRs, which represents the cumulative toppling probability of a theoretical random PBR as a function of PGA. The fragility distribution is then used to eliminate logic-tree branches that produce PGA hazard curves that would topple the random PBR with a greater than 95% probability (i.e., less than 5% survival probability) over a time period of 24 ka (youngest PBR fragility age). The mean 10 ka spectrum of the remaining hazard estimates is then recommended as the SEE spectrum for the dam site. This SEE spectrum has a PGA of 0.55g, which is significantly reduced from the 0.96g obtained for a preliminary version of the SEE spectrum. The reduction is due to the combined effects of the PBR constraints and a substantial update of the probabilistic seismic hazard model. The study serves as an important proof-of-concept for future applications of FGFs in engineering design. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

248. Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations

Author

Van Houtte Margriet, Lecocq Pierre, Van Craenenbroeck Elke, Van der Borght Koen, Van Kerckhove Barbara, Bacheler Lee, Verbeke Geert, and van Vlijmen Herman

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Biology (General), QH301-705.5
Abstract

Abstract Background Linear regression models are used to quantitatively predict drug resistance, the phenotype, from the HIV-1 viral genotype. As new antiretroviral drugs become available, new resistance pathways emerge and the number of resistance associated mutations continues to increase. To accurately identify which drug options are left, the main goal of the modeling has been to maximize predictivity and not interpretability. However, we originally selected linear regression as the preferred method for its transparency as opposed to other techniques such as neural networks. Here, we apply a method to lower the complexity of these phenotype prediction models using a 3-fold cross-validated selection of mutations. Results Compared to standard stepwise regression we were able to reduce the number of mutations in the reverse transcriptase (RT) inhibitor models as well as the number of interaction terms accounting for synergistic and antagonistic effects. This reduction in complexity was most significant for the non-nucleoside reverse transcriptase inhibitor (NNRTI) models, while maintaining prediction accuracy and retaining virtually all known resistance associated mutations as first order terms in the models. Furthermore, for etravirine (ETR) a better performance was seen on two years of unseen data. By analyzing the phenotype prediction models we identified a list of forty novel NNRTI mutations, putatively associated with resistance. The resistance association of novel variants at known NNRTI resistance positions: 100, 101, 181, 190, 221 and of mutations at positions not previously linked with NNRTI resistance: 102, 139, 219, 241, 376 and 382 was confirmed by phenotyping site-directed mutants. Conclusions We successfully identified and validated novel NNRTI resistance associated mutations by developing parsimonious resistance prediction models in which repeated cross-validation within the stepwise regression was applied. Our model selection technique is computationally feasible for large data sets and provides an approach to the continued identification of resistance-causing mutations.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results